home

OVERVIEW

Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China.

With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.

LEARN MORE

OUR STRATEGY

Enabling value creation by investing in Chinese subsidiaries of foreign companies active in the biomedical outside China

GIBF partners with selected companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders.

EXPLORE

PORTFOLIO

Companies' Overview

Partnering with top-tier international life sciences companies offering innovative solutions to Chinese healthcare needs.

COMPANY

InMode (NASDAQ: INMD) (Exit)

SECTOR

Medical Device

COMPANY

G-Medical (NASDAQ: GMVD)

SECTOR

Medical Device

COMPANY

CarboFix

SECTOR

Medical Device

VIEW ALL

OUR PEOPLE

Meet Our Management

Where global leaders in life sciences meet local talents to achieve cross-border investments and companies' formation.

MEET THE TEAM

Latest

News

VIEW ALL

Latest

News

VIEW ALL

Nectin Therapeutics and Immunome Inc. have reached a collaboration on monoclonal antibodies

Nectin Therapeutics, Ltd., the parent company of Guangzhou Nectin Pharmaceutical Co., Ltd., a project invested by GIBF2 recently announced a global exclusive license agreement with Immunome Inc. for a monoclonal antibody molecule.

Congratulations! Prof. Shlomo Noy, a partner of GIBF, has co-founded the medical device company Innovalve, which has been acquired by the American medical device giant Edwards Lifesciences for $300 million

Recently, the American medical device giant Edwards Lifesciences announced the completion of the acquisition of Innovalve Bio Medical (hereinafter referred to as Innovalve), a spin-off from the Sheba Medical Center in Israel, for $300 million in cash. The acquisition plan is expected to be completed by the end of 2024, at which time Innovalve will be integrated into Edwards Lifesciences' Transcatheter Mitral and Tricuspid Valve Therapies (TMVT) 'product group, a news that has attracted widespread attention in the biomedical field.

GIBF invests $10 Million in Nectin Therapeutics to Advance Novel Pipeline of First-in-Class Immunotherapies and Antibody Drug Conjugates

(6 May, 2024) Guangzhou-Israel Biotechnology Fund (GIBF) announced today that it has invested $10 million in Nectin Therapeutics Ltd, proceeds from financing to support ongoing clinical development of lead program targeting PVR as well as IND-enabling activities for multiple ADC candidates.